These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 29962472)

  • 1. [Sodium-Glucose Transporters as a Therapeutic Target for Diabetes from the Viewpoint of Drug Discovery and Pharmacotherapy].
    Miyamoto L; Tsuchiya K
    Yakugaku Zasshi; 2018; 138(7):933-938. PubMed ID: 29962472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.
    Washburn WN
    Expert Opin Ther Pat; 2009 Nov; 19(11):1485-99. PubMed ID: 19852718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
    Rajeev SP; Cuthbertson DJ; Wilding JP
    Diabetes Obes Metab; 2016 Feb; 18(2):125-34. PubMed ID: 26403227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'.
    Chan HW; Ashan B; Jayasekera P; Collier A; Ghosh S
    Diabetes Metab Syndr; 2012; 6(4):224-8. PubMed ID: 23199545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter inhibitors for diabetes.
    Isaji M
    Curr Opin Investig Drugs; 2007 Apr; 8(4):285-92. PubMed ID: 17458177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents.
    Choi CI
    Molecules; 2016 Aug; 21(9):. PubMed ID: 27618891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor].
    Takasu T; Takakura S; Hamada K
    Nihon Yakurigaku Zasshi; 2016; 148(5):266-271. PubMed ID: 27803440
    [No Abstract]   [Full Text] [Related]  

  • 9. [From the discovery of phlorizin (a Belgian story) to SGLT2 inhibitors].
    Valdes-Socin H; Scheen AJ; Jouret F; Grosch S; Delanaye P
    Rev Med Liege; 2022 Mar; 77(3):175-180. PubMed ID: 35258866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
    Lapuerta P; Zambrowicz B; Strumph P; Sands A
    Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT inhibitors as new therapeutic tools in the treatment of diabetes.
    Kinne RK; Castaneda F
    Handb Exp Pharmacol; 2011; (203):105-26. PubMed ID: 21484569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT inhibitors: a novel target for diabetes.
    Kanwal A; Banerjee SK
    Pharm Pat Anal; 2013 Jan; 2(1):77-91. PubMed ID: 24236972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibitors race to enter type-2 diabetes market.
    Sheridan C
    Nat Biotechnol; 2012 Oct; 30(10):899-900. PubMed ID: 23051788
    [No Abstract]   [Full Text] [Related]  

  • 15. Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology.
    Ferrannini E
    Cell Metab; 2017 Jul; 26(1):27-38. PubMed ID: 28506519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current status and issues of clinical development of novel anti-diabetic drugs].
    Kimura T; Kaku K
    Nihon Rinsho; 2013 Nov; 71(11):2030-7. PubMed ID: 24397179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.
    Nair S; Wilding JP
    J Clin Endocrinol Metab; 2010 Jan; 95(1):34-42. PubMed ID: 19892839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [SGLT inhibitor (T-1095)].
    Saito A; Seiyaku T; Tsujihara K
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():588-93. PubMed ID: 12387055
    [No Abstract]   [Full Text] [Related]  

  • 19. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
    Gallo LA; Wright EM; Vallon V
    Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.
    Rosenwasser RF; Rosenwasser JN; Sutton D; Choksi R; Epstein B
    Drugs Today (Barc); 2014 Nov; 50(11):739-45. PubMed ID: 25525634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.